GlassScriptPhysician profile
Thaddaeus M Poe
NPI 1598855967
$815.29
in general payments reported to CMS, 2019-2025
21 companies · $14.58 in 2025
The $14.58 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153 · 2020: $90.60 · 2021: $396 · 2023: $112 · 2024: $48.84 · 2025: $14.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $175.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $119.50 | 2019-2021 | |
| Novo Nordisk INC | $109.05 | 2019-2021 | |
| Glaxosmithkline, LLC. | $86.78 | 2023-2024 | Shingrix, Arexvy, Bexsero |
| Abbvie INC. | $66.59 | 2021 | |
| Exact Sciences Corporation | $64.30 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $40.94 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $38.83 | 2021 | |
| Biogen, INC. | $36.56 | 2021 | |
| Jazz Pharmaceuticals INC. | $36.27 | 2021 | |
| Genzyme Corporation | $30.47 | 2020-2021 | |
| Acorda Therapeutics, INC | $29.18 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $25.14 | 2020-2021 | |
| Pfizer INC. | $24.99 | 2019 | |
| Livanova USA, INC. | $24.21 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Lilly USA, LLC | $17.21 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $15.80 | 2019 | |
| Eisai INC. | $14.76 | 2019 | |
| Amarin Pharma, INC. | $12.37 | 2019 | |
| Allergan, INC. | $11.21 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $11.13 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thaddaeus Poe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.